RXST - Financial Snapshot

📈 Metrics for RXST

Price	$9.04
netCurrentAssetsPerShare	$6.18 netCurrentAssetsPerShare = (Current Assets - Total Liabilities) / Shares Outstanding
netTangibleAssetsPerShare	$6.79 netTangibleAssetsPerShare = (Total Assets - Intangibles - Total Liabilities) / Shares Outstanding
maxEarningPowerPerShare	$-2.24 maxEarningPowerPerShare = (EBITDA / EP_MULTIPLIER) / Shares Outstanding
adjustedEarningPower	$-2.41 adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
nonCashChargeToMKTCAP	0.22% nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
cashValuePerShare	$4.8 cashValuePerShare = (Cash + Short Term Investments - Total Liabilities) / Shares Outstanding

Data as of: Price 08-29-25 16:00 ET, Balance Sheet 2025-06-30, Income Statement 2025-06-30

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.